{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:04:01Z","timestamp":1792803841152,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejso.2025.111193","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T23:38:09Z","timestamp":1763854689000},"page":"111193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Stromal Tumor infiltrating lymphocytes (sTILs) as a prognostic biomarker in Ovarian Cancer After Neoadjuvant chemotherapy"],"prefix":"10.1016","volume":"52","author":[{"given":"Snita","family":"Sinukumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3295-0006","authenticated-orcid":false,"given":"Mufaddal","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nutan","family":"Jumle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmy S.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dileep","family":"Damodaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajna","family":"PV","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuba","family":"C","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasi","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9257-3444","authenticated-orcid":false,"given":"Taher","family":"Chachhodwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hareesh","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruna","family":"Prabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Sankaralingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2025.111193_bib1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejogrb.2019.03.010","article-title":"Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Short text of the French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARC AGY , and endorsed by INCa","volume":"236","author":"Lavoue","year":"2019","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"10.1016\/j.ejso.2025.111193_bib2","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"21","key":"10.1016\/j.ejso.2025.111193_bib3","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.3390\/cancers14215332","article-title":"Tumor-infiltrating lymphocytes (TILs) in epithelial ovarian cancer: heterogeneity, prognostic impact, and relationship with immune checkpoints","volume":"14","author":"Hudry","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"13","key":"10.1016\/j.ejso.2025.111193_bib4","doi-asserted-by":"crossref","first-page":"822","DOI":"10.21037\/atm-20-151","article-title":"Prognostic value of tumor-infiltrating lymphocytes in esophageal cancer: an updated meta-analysis of 30 studies with 5,122 patients","volume":"8","author":"Gao","year":"2020","journal-title":"Ann Transl Med"},{"issue":"4","key":"10.1016\/j.ejso.2025.111193_bib5","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3390\/biomedicines12040763","article-title":"Tumor-infiltrating lymphocytes (TILs) in breast cancer: prognostic and predictive significance across molecular subtypes","volume":"12","author":"Ciarka","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejso.2025.111193_bib6","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.3389\/fimmu.2019.02368","article-title":"Tumor-infiltrating Immune cells Act as a marker for prognosis in colorectal cancer","volume":"10","author":"Ye","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejso.2025.111193_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2018.07.025","article-title":"Patient inflammatory status and CD4+\/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer","volume":"151","author":"Pinto","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2025.111193_bib8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1186\/s12885-017-3585-x","article-title":"Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer","volume":"17","author":"James","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejso.2025.111193_bib9","first-page":"4557","article-title":"Stromal tumor-infiltrating lymphocytes evaluated on H&E-Stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma","volume":"17","author":"Hwang","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ejso.2025.111193_bib10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ygyno.2024.12.011","article-title":"Incorporating immune checkpoint inhibitors in epithelial ovarian cancer","volume":"193","author":"Bogani","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2025.111193_bib11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working group 2014","volume":"26","author":"Salgado","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2025.111193_bib12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv Anat Pathol"},{"issue":"1","key":"10.1016\/j.ejso.2025.111193_bib13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/IGC.0000000000000327","article-title":"Prognostic significance of Sugarbaker's peritoneal cancer index for the operability of ovarian carcinoma","volume":"25","author":"Lampe","year":"2015","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ejso.2025.111193_bib14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s13193-016-0505-5","article-title":"Cytoreductive surgery and peritonectomy procedures","volume":"7","author":"Mehta","year":"2016","journal-title":"Indian J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2025.111193_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","article-title":"Peritonectomy procedures","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2025.111193_bib16","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/s41467-018-03301-0","article-title":"Sensitive and frequent identification of high avidity neo-epitope specific CD8+ T cells in immunotherapy-naive ovarian cancer","volume":"9","author":"Bobisse","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejso.2025.111193_bib17","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/eji.200324181","article-title":"CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative","volume":"34","author":"Ghiringhelli","year":"2004","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ejso.2025.111193_bib18","doi-asserted-by":"crossref","first-page":"i11","DOI":"10.1093\/annonc\/mdw084","article-title":"Opportunities in immunotherapy of ovarian cancer","volume":"27","author":"Coukos","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2025.111193_bib19","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1002\/cam4.3942","article-title":"Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer","volume":"10","author":"Zhang","year":"2021","journal-title":"Cancer Med"},{"issue":"51","key":"10.1016\/j.ejso.2025.111193_bib20","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.ejso.2025.111193_bib21","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1158\/1078-0432.CCR-13-1877","article-title":"Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer","volume":"20","author":"Webb","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejso.2025.111193_bib22","first-page":"1","article-title":"Immune therapy opportunities in ovarian cancer","volume":"40","author":"Kandalaft","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ejso.2025.111193_bib23","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2025.111193_bib24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ygyno.2016.03.008","article-title":"PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer","volume":"141","author":"Webb","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2025.111193_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211008399","article-title":"Cell therapies in ovarian cancer","volume":"13","author":"Sarivalasis","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2025.111193_bib26","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13048-024-01533-x","article-title":"The predictive role of PD-L1 expression and CD8 + TIL levels in determining the neoadjuvant chemotherapy response in advanced ovarian cancer","volume":"17","author":"Aliyeva","year":"2024","journal-title":"J Ovarian Res"},{"issue":"1","key":"10.1016\/j.ejso.2025.111193_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12885-022-10404-x","article-title":"PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers","volume":"23","author":"Alwosaibai","year":"2023","journal-title":"BMC Cancer"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074879832501621X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074879832501621X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T07:59:51Z","timestamp":1767945591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S074879832501621X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S074879832501621X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2025.111193","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stromal Tumor infiltrating lymphocytes (sTILs) as a prognostic biomarker in Ovarian Cancer After Neoadjuvant chemotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2025.111193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111193"}}